## Millard H Lambert

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11379337/publications.pdf

Version: 2024-02-01

46 papers

14,035 citations

38 h-index 233338 45 g-index

46 all docs

46 docs citations

46 times ranked

12004 citing authors

#	Article	IF	CITATIONS
1	Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor- $\hat{l}^3$ . Nature, 1998, 395, 137-143.	13.7	1,818
2	Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor $\hat{l}_{\pm}$ . Nature, 1997, 385, 733-736.	13.7	1,636
3	A Critical Assessment of Docking Programs and Scoring Functions. Journal of Medicinal Chemistry, 2006, 49, 5912-5931.	2.9	1,429
4	Molecular Recognition of Fatty Acids by Peroxisome Proliferator–Activated Receptors. Molecular Cell, 1999, 3, 397-403.	4.5	1,052
5	Crystal Structure of the Glucocorticoid Receptor Ligand Binding Domain Reveals a Novel Mode of Receptor Dimerization and Coactivator Recognition. Cell, 2002, 110, 93-105.	13.5	747
6	The Human Nuclear Xenobiotic Receptor PXR: Structural Determinants of Directed Promiscuity. Science, 2001, 292, 2329-2333.	6.0	743
7	The Pregnane X Receptor: A Promiscuous Xenobiotic Receptor That Has Diverged during Evolution. Molecular Endocrinology, 2000, 14, 27-39.	3.7	607
8	Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARα. Nature, 2002, 415, 813-817.	13.7	598
9	Peroxisome Proliferator–Activated Receptor γ and Metabolic Disease. Annual Review of Biochemistry, 2001, 70, 341-367.	5.0	552
10	Asymmetry in the PPAR $\hat{1}^3$ /RXR $\hat{1}^\pm$ Crystal Structure Reveals the Molecular Basis of Heterodimerization among Nuclear Receptors. Molecular Cell, 2000, 5, 545-555.	4.5	547
11	Identification of a Novel Human Constitutive Androstane Receptor (CAR) Agonist and Its Use in the Identification of CAR Target Genes. Journal of Biological Chemistry, 2003, 278, 17277-17283.	1.6	380
12	Atomic Structure of PDE4: Insights into Phosphodiesterase Mechanism and Specificity. Science, 2000, 288, 1822-1825.	6.0	342
13	Pregnane X Receptor (PXR), Constitutive Androstane Receptor (CAR), and Benzoate X Receptor (BXR) Define Three Pharmacologically Distinct Classes of Nuclear Receptors. Molecular Endocrinology, 2002, 16, 977-986.	3.7	319
14	Novel selective small molecule agonists for peroxisome proliferator-activated receptor δ (PPARδ)—synthesis and biological activity. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 1517-1521.	1.0	301
15	The Drosophila Orphan Nuclear Receptor DHR38 Mediates an Atypical Ecdysteroid Signaling Pathway. Cell, 2003, 113, 731-742.	13.5	226
16	A Structural Basis for Constitutive Activity in the Human CAR/RXRα Heterodimer. Molecular Cell, 2004, 16, 919-928.	4.5	219
17	A Ligand-mediated Hydrogen Bond Network Required for the Activation of the Mineralocorticoid Receptor. Journal of Biological Chemistry, 2005, 280, 31283-31293.	1.6	188
18	X-ray Crystal Structure of the Liver X Receptor $\hat{l}^2$ Ligand Binding Domain. Journal of Biological Chemistry, 2003, 278, 27138-27143.	1.6	187

#	Article	IF	CITATIONS
19	Structural Disorder in the Complex of Human Pregnane X Receptor and the Macrolide Antibiotic Rifampicin. Molecular Endocrinology, 2005, 19, 1125-1134.	3.7	185
20	Activation of Nuclear Receptors. Structure, 2003, 11, 741-746.	1.6	161
21	TACE and other ADAM proteases as targets for drug discovery. Drug Discovery Today, 2001, 6, 417-426.	3.2	158
22	Specific Sequence Elements Are Required for the Expression of Functional Tumor Necrosis Factor-α-converting Enzyme (TACE). Journal of Biological Chemistry, 1999, 274, 30563-30570.	1.6	145
23	The first completed genome sequence from a teleost fish (Fugu rubripes) adds significant diversity to the nuclear receptor superfamily. Nucleic Acids Research, 2003, 31, 4051-4058.	6.5	137
24	Structural basis for autorepression of retinoid X receptor by tetramer formation and the AF-2 helix. Genes and Development, 2000, 14, 2229-2241.	2.7	120
25	X-ray Crystal Structures of the Estrogen-related Receptor-γ Ligand Binding Domain in Three Functional States Reveal the Molecular Basis of Small Molecule Regulation. Journal of Biological Chemistry, 2006, 281, 37773-37781.	1.6	120
26	Pharmacophore Analysis of the Nuclear Oxysterol Receptor LXRα. Journal of Medicinal Chemistry, 2001, 44, 886-897.	2.9	118
27	Substituted 2-[(4-Aminomethyl)phenoxy]-2-methylpropionic Acid PPARα Agonists. 1. Discovery of a Novel Series of Potent HDLc Raising Agents. Journal of Medicinal Chemistry, 2007, 50, 685-695.	2.9	115
28	Crystal Structures of the Catalytic Domain of Phosphodiesterase 4B Complexed with AMP, 8-Br-AMP, and Rolipram. Journal of Molecular Biology, 2004, 337, 355-365.	2.0	113
29	D3R Grand Challenge 3: blind prediction of protein–ligand poses and affinity rankings. Journal of Computer-Aided Molecular Design, 2019, 33, 1-18.	1.3	104
30	Structure of Rev-erbl̂± bound to N-CoR reveals a unique mechanism of nuclear receptor–co-repressor interaction. Nature Structural and Molecular Biology, 2010, 17, 808-814.	3.6	80
31	Progesterone Receptor Ligand Binding Pocket Flexibility:  Crystal Structures of the Norethindrone and Mometasone Furoate Complexes. Journal of Medicinal Chemistry, 2004, 47, 3381-3387.	2.9	78
32	Alteration of a Single Amino Acid in Peroxisome Proliferator-Activated Receptor-α (PPARα) Generates a PPARδ Phenotype. Molecular Endocrinology, 2000, 14, 733-740.	3.7	71
33	Design of Selective and Soluble Inhibitors of Tumor Necrosis Factor-α Converting Enzyme (TACE). Journal of Medicinal Chemistry, 2001, 44, 4252-4267.	2.9	70
34	Pattern recognition in the prediction of protein structure. I. Tripeptide conformational probabilities calculated from the amino acid sequence. Journal of Computational Chemistry, 1989, 10, 770-797.	1.5	56
35	Subtype Specific Effects of Peroxisome Proliferator-Activated Receptor Ligands on Corepressor Affinity. Biochemistry, 2003, 42, 9278-9287.	1.2	44
36	Interactions that determine the assembly of a retinoid X receptor/corepressor complex. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 5842-5847.	3.3	42

#	Article	IF	CITATIONS
37	Pattern recognition in the prediction of protein structure. II. Chain conformation from a probability-directed search procedure. Journal of Computational Chemistry, 1989, 10, 798-816.	1.5	40
38	Identification of a series of oxadiazole-substituted α-isopropoxy phenylpropanoic acids with activity on PPARα, PPARγ, and PPARδ. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 2385-2388.	1.0	40
39	Pattern recognition in the prediction of protein structure. III. An importance-sampling minimization procedure. Journal of Computational Chemistry, 1989, 10, 817-831.	1.5	35
40	Synthesis and biological activity of l-tyrosine-based PPAR $\hat{l}^3$ agonists with reduced molecular weight. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 3111-3113.	1.0	32
41	Substrate Specificity and Novel Selective Inhibitors of TNF-α Converting Enzyme (TACE) from Two-Dimensional Substrate Mapping. Combinatorial Chemistry and High Throughput Screening, 2005, 8, 327-339.	0.6	24
42	N-Hydroxyformamide peptidomimetics as TACE/Matrix metalloprotease inhibitors: oral activity via P1 $\hat{a}$ $\in$ 2 isobutyl substitution. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 2147-2151.	1.0	22
43	Co-crystal structure guided array synthesis of PPARγ inverse agonists. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 3916-3920.	1.0	20
44	Structural insights into regulation of nuclear receptors by ligands. Nuclear Receptor Signaling, 2003, 1, nrs.01004.	1.0	13
45	Design, Structure, and Function of Novel PPAR Ligands. Medical Science Symposia Series, 2002, , 5-8.	0.0	1
46	Structural Mechanisms of Ligand-Mediated Signaling by Nuclear Receptors. , 2003, , 21-24.		0